Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Mercaptopurine
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Mercaptopurine 50mg tablets
0801030L0AAAAAA
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | 16,101 |
|
Mercaptopurine 10mg tablets
0801030L0AAABAB
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | 243 |
|
Hanixol 50mg tablets
0801030L0BDAAAA
|
Hanixol | Mercaptopurine | Malignant Disease and Immunosuppression | 155 |
|
Mercaptopurine 20mg/ml oral suspension
0801030L0AAAQAQ
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | 135 |
|
Mercaptopurine 10mg capsules
0801030L0AAAGAG
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | 76 |
|
Mercaptopurine 25mg capsules
0801030L0AAALAL
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | 18 |
|
Mercaptopurine 25mg tablets
0801030L0AAAJAJ
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | 11 |
|
Mercaptopurine 75mg tablets
0801030L0AAANAN
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | 10 |
|
Xaluprine 20mg/ml oral suspension
0801030L0BCABAQ
|
Xaluprine | Mercaptopurine | Malignant Disease and Immunosuppression | 10 |
|
Puri-Nethol 50mg tablets
0801030L0BBAAAA
|
Puri-Nethol | Mercaptopurine | Malignant Disease and Immunosuppression | 2 |
|
Mercaptopurine 12.5mg capsules
0801030L0AAASAS
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | No data available |
|
Mercaptopurine 20mg capsules
0801030L0AAARAR
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | No data available |
|
Mercaptopurine 25mg/5ml oral suspension
0801030L0AAAHAH
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | No data available |
|
Mercaptopurine 30mg capsules
0801030L0AAAMAM
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | No data available |
|
Mercaptopurine 45mg/5ml oral suspension
0801030L0AAAKAK
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | No data available |
|
Mercaptopurine 50mg/5ml oral suspension
0801030L0AAAFAF
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | No data available |
|
Mercaptopurine 5mg/5ml oral suspension
0801030L0AAACAC
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | No data available |
|
Mercaptopurine 75mg capsules
0801030L0AAAPAP
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | No data available |
|
Mercaptopurine 75mg/5ml oral suspension
0801030L0AAAIAI
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.